Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes

In conclusion, to improve the effectiveness of Ropeg, we suggest increasing the dose and using it earl ier driven by high phlebotomy need in the first 6 months post-diagnosis.

Source: Annals of Hematology - December 7, 2023 Category: Hematology Source Type: research